Refractory, primary Central Nervous System Neoplasm Active Not Recruiting Phase 1 Trials for Irinotecan (DB00762)

Back to Refractory, primary Central Nervous System Neoplasm

Also known as: Refractory Primary Central Nervous System Neoplasm

IndicationStatusPhase
DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02975882Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsTreatment
NCT03323034Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaTreatment